No Data
No Data
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $18
Iovance Biotherapeutics (IOVA) Receives a Buy From Stifel Nicolaus
Jefferies Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $18
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance
Iovance Biotherapeutics Price Target Lowered to $30 From $34 at Chardan